Introduction
============

With increasing incidence and mortality, colorectal cancer (CRC) has become the third most common cause of cancer death worldwide[@B1]. In China, mortality caused by CRC was estimated to reach 191,000 in 2015[@B2]. In all these deaths, the development of distant metastatic disease was the main cause of death, and the liver was the most common site of CRC metastasis. Approximately 20 - 25 % of CRC patients were initially diagnosed with synchronous liver metastases, and approximately half of the patients developed metachronous liver metastases after primary tumor resection[@B3], [@B4]. Liver metastases resection is the only known option for curing patients with colorectal liver metastases[@B5], [@B6]. However, approximately 75 % of patients will experience recurrence within 2 years[@B7]. Recurrence after colorectal liver metastases resection is common, with approximately 30 % of intrahepatic recurrence patients and more than 50 % extrahepatic recurrence[@B8], [@B9].Thus, clinical biomarkers are needed to find suitable patients for corresponding individual interventions.

Hepatitis B virus (HBV) is the most common cause of chronic liver disease in the world, with an estimated 250 - 400 million people chronically infected with HBV [@B10]. China has a high prevalence of HBV infection, with 97 million HBV carriers and at least 20 million individuals with an active chronic hepatitis B infection[@B11]. HBV infection was previously shown to play an important role in the progression of hepatocellular carcinoma(HCC) and to present with increased intrahepatic metastasis, thus suggesting the role of HBV infection in survival[@B12].

Several reports on the relationship between HBV infection and liver metastasis in CRC are available. Utsunomiya et al.[@B13] reported that CRC patients infected with HBV or hepatitis C virus (HCV)scarcely present with liver metastases. Another study reported that compared with non-infected patients, HBV-infected CRC patients exhibited a reduced liver metastasis rate and increased survival rate[@B14], [@B15]. Since HBV-infected CRC patients presented with a low possibility of liver metastases and better prognosis, we hypothesize that HBV infection is associated with better prognosis of CRLM patients undergoing liver metastases resection. In this study, we examined the association between HBV infection and the survival of CRLM patients undergoing liver metastases resection to investigate the predictive value of HBV infection in screening for high-risk patients for individual treatment.

Materials and Methods
=====================

Patients
--------

A retrospective analysis was conducted by reviewing the clinicopathological data of 289 CRLM patients who underwent radical liver resection from September 1999 to August 2015 at Sun Yat-sen University Cancer Center (Guangzhou, China). Patients who met the following criteria were enrolled: 1) histologically confirmed colorectal adenocarcinoma, 2) metastases limited to the liver before liver resection, 3) R0 resection for primary lesion and metastases, and 4) no other cancer during follow-up. Patients were excluded if they had extrahepatic metastatic lesions, died in the perioperative period or underwent palliative liver resection. The primary tumor was completely removed, and liver metastases were radically resected in all eligible patients. Clinicopathological features of CRLM patients; tumor characteristics; and the time of hepatectomy, relapse and last follow-up were all reviewed from the medical records and the follow-up system of Sun Yat-sen University Cancer Center. The present study was undertaken according to the ethical standards of the 1964 Declaration of Helsinki. Institutional Review Board approval was obtained from independent ethics committees at the Sun Yat-sen University Cancer Center with a waiver of informed consent because this research was retrospective and did not involve accessing any patient identification data.

Serologic assay for CRLM patients
---------------------------------

Routine peripheral blood biochemical tests and serum tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), were acquired about one week before liver metastases resection. CEA levels above 5 ng/ml and CA19-9 levels above 35U/ml were considered to be elevated. Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), hepatitis B e-antigen (HBeAg), hepatitis B e-antibody (anti-HBe), and hepatitis B core antibody (anti-HBc) levels were examined in all patients by enzyme-linked immunosorbent assay (ELISA), and HBV DNA was detected by polymerase chain reaction(PCR). Blood samples were collected from all CRLM patients at the first visit, and serum samples were separated for the HBV infection test. A serum HBV DNA result of \>1000 copies/ml was considered positive. According to the HBsAg status at their first visit, patients who were HBsAg-positive or HBsAg-negative were divided into an HBV-infected or non-infected group. The infected group was further subdivided into two groups based on HBeAg and serum HBV DNA detection. Chronic hepatitis B (CHB) patients, defined as patients having active HBV replication, were characterized by being HBsAg-positive and positive for either HBeAg or HBV DNA. Inactive HBsAg carriers (IC), indicating HBV infection but without active replication, were identified as HBsAg-positive and negative for both HBeAg and HBV DNA[@B16], [@B17].

Follow-up of patients
---------------------

All patients were followed up after hospital discharge. The patients were followed up every 3 months in the first 2 years after liver resection and then semi-annually until 3 years after liver resection. The follow-up evaluation included a routine blood test, tests for the tumor markers CEA and CA19-9, abdominal ultrasonography, and a chest radiograph. A chest computed tomography scan, abdominal/pelvic magnetic resonance imaging, and a colonoscopy were performed annually. The follow-up period was terminated in June 2017.

Statistical analysis
--------------------

Values are presented as the median (range) or percentage, as appropriate. Differences in baseline clinicopathological characteristics between the two groups were assessed by chi-square test or Fisher\'s exact test. Progression-free survival (PFS) was defined as the time from the date of liver resection to the date of disease progression, date of death due to any cause or date of the last follow-up. Overall survival (OS) was defined from the date of liver resection until the date of death or last follow-up. OS and PFS curves were evaluated with the Kaplan-Meier method, and the significance differences between the HBsAg-positive and HBsAg-negative groups were compared by using log-rank test. Univariate and multivariate analyses with Cox proportional hazard regression models were performed to determine the hazard ratio (HR) of each prognostic factor. Covariates with *P* values\<0.05 in univariate analysis were subjected to multivariate analysis. All statistical analyses were performed using SPSS 20.0 statistical software (IBM, NY, USA) and GraphPad Prism version 6.01 (GraphPad Software, Inc, La Jolla, CA, USA). A two-tailed *P* value \< 0.05was interpreted as statistically significant.

Results
=======

1. Clinicopathological characteristics of CRLM patients {#Section1}
-------------------------------------------------------

A total of 289 cases were qualified for the analyses. Liver metastasis occurred in these 289 patients, including 190 cases with synchronous liver metastasis and 99 cases with metachronous liver metastasis. According to the HBsAg infection status, 35 patients (12.1 %) were distributed to the HBV infection group, and 254 patients (87.9 %) were distributed to the non-infected group. Among the 35 HBV-infected CRLM patients, except for 9 HBeAg-negative patients without HBV DNA detection, CHB was identified in 11 patients (3.8 %), and IC was identified in 15patients (5.2 %).

As shown in Table [1](#T1){ref-type="table"}, the median age of the 289 patients was 57 years (range, 25 - 82 years), with 185 (64.0 %) males and 104 (36.0 %) females. HBV infection status was significantly associated with fewer liver metastases (P = 0.025) and smaller-sized liver metastases (P = 0.049) (Table [2](#T2){ref-type="table"}).

2. Overall survival and progression-free survival difference according to HBV infection status {#Section2}
----------------------------------------------------------------------------------------------

The median follow-up time after liver resection was 34 months (range 1 - 126) for all 289 patients. Overall, from the start of the study until the date of last follow-up, 115 patients (39.8 %) died of CRC, and 174 patients (60.2 %) had intrahepatic or extrahepatic recurrence. Postoperative recurrence in HBV-infected patients was significantly lower than that in non-infected patients (P = 0.009) (Table [3](#T3){ref-type="table"}). The 1-, 3-, and the 5-year OS rates were94.0%, 66.0%, and 52.4%, respectively, and the 1-, 3-, 5-year PFS rates were 62.9 %, 41.5 %, and 36.1 %, respectively. The results showed that OS and PFS of the HBV-infected CRLM patients were significantly better than the rates in the non-infected patients (Fig. [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B). The 1-, 3-, and 5-year OS rates were 97.0 %, 75.0 %, and 75.0 % in the HBV-infected group and 93.6 %, 64.8 %, and 49.8 % in the non-infected group, respectively (log-rank test, P = 0.031). Similarly, the 1-, 3-, and 5-year PFS rates were 79.0 %, 55.9 %, and 55.9 % in the infected group and 60.8 %, 39.6 %, and 33.7 % in the non-infected group, respectively (log-rank test, P = 0.034).

3. Prognostic factors for overall survival and progression-free survival {#Section3}
------------------------------------------------------------------------

For patients with CRLM undergoing liver resection, univariate analysis revealed that older patients (HR,1.515; 95 % confidence interval(CI),1.048 - 2.192; P = 0.027), HBV non-infection (HR,2.258; 95 % CI,1.050 - 4.853; P = 0.037),lower albumin (ALB) level (g/dL) (HR,0.479; 95 % CI,0.250 - 0.918; P = 0.027), higher lactate dehydrogenase (LDH)level (IU/L) (HR,1.772; 95 % CI,1.092 - 2.876;P = 0.02), higher gamma-glutamyl transpeptidase (GGT) level (IU/L) (HR, 1.759; 95 % CI, 1.188 - 2.604; P = 0.005), multiple liver metastatic segments (HR, 1.815; 95 % CI, 1.241 - 2.655; P = 0.002), more liver metastases(HR, 1.827; 95 % CI,1.256 - 2.657; P = 0.002), and patients undergoing neoadjuvant chemotherapy (HR, 1.817; 95 % CI, 1.252 - 2.638; P = 0.002) were associated with worse OS (Table [4](#T4){ref-type="table"}). For PFS, lymph node metastasis (HR, 1.800; 95 % CI, 1.295 - 2.503; P \< 0.001), smaller-sized primary tumor (≤ 4 cm) (HR, 1.534; 95 % CI,1.062 - 2.216; P = 0.023), HBV non-infection (HR,1.779; 95 % CI,1.030 - 3.072; P = 0.039), higher GGT level (HR, 1.561; 95 % CI, 1.128 - 2.162; P = 0.007), multiple liver metastatic segments (HR, 1.847; 95 % CI, 1.360 - 2.507; P \< 0.001), more liver metastases (HR, 1.94; 95 % CI, 1.432 - 2.628; P \< 0.001),larger-sized metastases tumor (\>2.5 cm) (HR, 1.355; 95 % CI, 1.002 - 1.831; P = 0.048), closer liver resection surgery margin(≤ 0.5 cm) (HR,1.755; 95 % CI,1.195 - 2.578; P = 0.004), higher CEA level (HR, 1.403; 95 % CI, 1.014 - 1.942; P = 0.041), and patients undergoing neoadjuvant chemotherapy (HR, 2.282; 95 % CI, 1.681 - 3.099; P \< 0.001) were associated with worse PFS (Table [4](#T4){ref-type="table"}).

A multivariate Cox proportional hazard model was used to further analyze the prognostic factors that were significantly associated with OS or PFS in univariate analysis including HBV infection status. As shown in Table [4](#T4){ref-type="table"}, the multivariate analysis demonstrated that HBV non-infection (HR,2.242; 95 % CI,1.035 - 4.853; P = 0.041) as well as older age (HR,1.702; 95 % CI, 1.171-2.474; P = 0.005), higher blood GGT level (HR, 1.597; 95 % CI, 1.073 - 2.377; P = 0.021), multiple liver metastatic segments (HR, 1.538; 95 % CI, 1.034 - 2.286; P = 0.033) and neoadjuvant chemotherapy (HR, 1.632; 95 % CI, 1.103 - 2.416; P = 0.014) were all independent predictors of worse OS for patients with CRLM undergoing liver resection. Furthermore, lymph node metastasis (HR,2.023; 95 % CI,1.229 - 3.329; P = 0.006), blood GGT level (HR, 1.806; 95 % CI, 1.099 - 2.967; P = 0.02), and number of liver metastases (HR, 1.748; 95 % CI, 1.043 - 2.929; P = 0.034), but not HBV infection, were independent predictors of PFS.

Discussion
==========

In this study, 289 colorectal liver metastases patients all underwent a radical liver resection. There were fewer and smaller-sized liver metastases in the HBV-infected group than in the non-infected group, indicating that HBV infection and clinicopathological features of CRLM patients were significantly correlated. In this study, the OS and PFS rates of CRLM patients in the HBV-infected group were higher than those in the non-infected group (P=0.031 and P = 0.034, respectively), and there was a significant difference in survival rate between these two groups, suggesting that HBV infection may have a strong correlation with survival of CRLM patients undergoing liver resection. We also found that HBV-infected CRLM patients had less postoperative recurrence than non-infected patients (P = 0.009). In addition, the recurrence pattern between these two groups differed. HBV-infected patients were more likely to have extrahepatic metastases than HBV non-infected patients, who had intrahepatic metastases; however, this result was not statistically significant (P = 0.051). In multivariate Cox analysis, HBV infection was identified as an independent factor for better OS but not an independent factor for PFS. We also analyzed the difference in the survival rate between patients in the CHB and IC groups, but there was no significant difference. (Figure [S1](#SM0){ref-type="supplementary-material"}.)

Reports are available on the relationship between HBV infection and liver metastasis in CRC patients. In a previous cohort study[@B15], HBV infection was demonstrated to decrease the risk of liver metastasis in patients with CRC and elevate the surgical resection rate of liver metastatic lesions. Utsunomiya et al*.* reported that CRC seldom metastasized to the liver in patients infected with HBV or HCV; however, most of the patients in the study were HCV-infected[@B13].

Song et al. suggested that chronic HBV infection with viral replication could reduce liver metastasis and prolong the survival of CRC patients[@B14]. In our study, we also demonstrated that HBV-negative CRLM patients are more likely to develop recurrence after liver resection than HBV-positive patients and that the former are more likely to develop intrahepatic recurrence than the latter. The reasons why HBV-positive patients scarcely metastasize to the liver or are not prone to intrahepatic recurrence are not completely understood, but some investigations have been conducted. Approximately 5241 consecutive autopsies in the Trieste area and 6511 consecutive autopsies in the Tokyo-Chiba area were analyzed to study the frequency of liver metastases in cirrhosis[@B18]. The results showing that metastases in cirrhotic liver are rare were similar in both areas, which implied that in HBV-infected patients, the scarce metastasis of CRC to the liver maybe due to the hostile "soil" in the liver caused by viral replication.

However, whether the liver-associated immunity in HBV-infected patients hindered liver metastasis of CRC and prolonged survival needs further exploration. Viral clearance and disease pathogenesis are largely mediated by the adaptive immune response in HBV infection [@B19]. Previous studies reported that the liver has a considerable number of innate immune cells, especially lymphocytes including natural killer cells[@B20]. Several cells with phagocytic and antigen-presenting properties, including Kupffer cells and dendritic cells, play an important role in the local innate immunity of the liver[@B21].HBV receptors are expressed in a variety of extrahepatic cells, and HBV can alter the biological characteristics of these cells through their receptors[@B22].In addition, it has been reported that HBV replication can activate specific lytic pathways of cell damage by cytotoxic lymphocytes (CTLs)and Kupffer cells[@B23]. It is widely believed that the HBV specific CD8+ T cell response plays a fundamental role in viral clearance. Investigation of experimentally induced hepatic metastasis of colon cancer indicated that changes in liver-related immunity may play an important role in the impediment of liver metastasis[@B24].

In HBV transgenic mice, the CTL response to HBV by inducing several inflammatory factors. Indeed, they purge HBV replication in the liver by secreting type 1 inflammatory cytokines to limite virus spread to uninfected cells [@B25]. Furthermore, HBV replication is inhibited by stimulus which could induce IFNγ or IFN α/β in the liver, including CD4+ T cells, NK and NKT cells, as well as toll-like receptor activation [@B26],[@B27]. In studies of HBV-infected chimpanzees, intrahepatic gene expression profiling in these animals revealed that the early phase of HBV clearance was associated with CD3, CD8 and IFNγ mRNA and other T cell-derived and interferon gamma (IFNγ)-stimulated genes [@B28],[@B29]. Furthermore, HBV replication can promote the production of tumor necrosis factor a (TNF-a) by residual immune cells as well as hepatocytes in the liver[@B30],[@B31], which can exhibit an antitumor effect on tumor cells. A previous study showed that the liver microenvironment in patients with HBV-positive liver metastases can greatly alter their gene expression profiles, and two significant clusters in the profile showed significant changes associated with gene products involved in immune function. In fact, over 30% of the genes in these clusters are related to immunity[@B23]. Another study on the interaction of tumor and stroma showed that liver-prone metastatic tumors were inherent in tumor cells and affected by the local environment of metastatic sites[@B32]. In conclusion, the soil (liver microenvironment) and activation of liver-associated immunity due to HBV infection may partially explain the reduction in the incidence of liver metastasis in CRC patients and the prolonged survival rate of CRLM patients undergoing liver resection. In our study, we found that the survival rates in the CHB and IC groups are similar. Thus, it is reasonable to postulate that HBV infection with or without HBeAg infection or viral replication may affect survival of colorectal liver metastases in patients undergoing liver resection.

There are a number of limitations to our study. First, our study included a retrospective study with a relatively small sample size of patients from a single-institution experience. Second, the follow-up period was not long enough, which may have resulted in bias during analysis. Third, molecular detections are lacking. This retrospective result did not consider the status of KRAS, NRAS, or BRAF expression, which may have an influence on disease progression. Accordingly, further investigations of KRAS, NRAS, and BRAF expression in tumor tissues are needed to elucidate the precise contribution to the development of CRLM together with HBV. Finally, a previous study found that maintaining a relatively low level of HBV DNA plays a strong protective role in the overall and long-term recurrence-free survival of patients with HBV-related HCC[@B33]. In our study, we did not analyze the effect of HBV DNA copy number on survival of CRLM patients undergoing liver resection because of the small sample population of HBV-positive patients and the lack of HBV DNA detection for several cases. Future studies should increase the sample size and include the effect of HBV viral load on survival of those patients. Therefore, objective prospective studies with more comprehensive clinical data and a longer follow-up period are needed to confirm our results.

In conclusion, we first found that HBV infection correlates with a good prognosis in infected patients; however, the mechanisms still need to be further explored and clarified. In clinical work, when HBsAg-positive patients may have two viable options for therapeutic regimens, patients can choose the less aggressive option. In addition, these patients can consider undertaking a less strict follow-up. However, larger and more objective prospective studies are needed to guide clinical decision making.

Supplementary Material {#SM0}
======================
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![**Correlation of hepatitis B surface antigen (HBsAg) status with progression-free survival and overall survival in 289 colorectal liver metastases (CRLM) patients.** Kaplan-Meier survival curve showing better progression-free survival (A) and overall survival (B) in HBsAg-positive CRLM patients.](jcav09p1560g001){#F1}

###### 

Baseline characteristics of 289 colorectal liver metastases patients

  Characteristics                                       n (%)
  ------------------------------------- --------------- -------------
  Sex                                   Male            185 (64.0)
                                        Female          104 (36.0)
  Age (years)                           \<=57           150 (51.9)
                                        \>57            139 (48.1)
  Primary tumor site^a^                 Colon           179 (62.2)
                                        Rectum          109 (37.8 )
  Primary tumor size (cm)^b^            \<=4            126 (61.2)
                                        \>4             80 (38.8)
  T stage (T1-3/T4)^c^                  T1-3            170 (64.2)
                                        T4              95 (35.8)
  N stage (N0/N1-2)^d^                  N0              110 (42.3)
                                        N1-2            150 (57.7)
  Histological grade (/ poor)^e^        Well/moderate   212 (86.2)
                                        Poor            34 (13.8)
  Albumin (g/dl)                        \<=35           272 (94.1)
                                        \>35            17 (5.9)
  CEA level (ng/ml)^f^                  \<=5            102 (37.1)
                                        \>5             173 (62.9)
  CA199 level (U/ml)^g^                 \<=35           185 (69.3)
                                        \>35            82 (30.7)
  Liver metastases tumor size (cm)^h^   \<=2.5          151 (53.0)
                                        \>2.5           134 (47.0)
  Liver metastases number               Single          147 (50.9)
                                        Multiple        142 (49.1)
  Liver metastases segments             Oligo           136 (47.1)
                                        Multiple        153 (52.9)
  HBV infection status^i^               Non infection   254 (90.7)
                                        CHB             11 (3.9)
                                        IC              15 (5.4)
  Liver metastases                      Synchronous     190 (65.7)
                                        Metachronous    99 (34.3)
  Hepatic resection timing              Synchronous     131 (45.3)
                                        Metachronous    158 (54.7)

Abbreviations: CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; HBV, hepatitis B virus; CHB, chronic hepatitis B; IC, inactive carriers.

^a^Data of 288 patients were available

^b^Data of 206 patients were available

^c^Data of 265 patients were available

^d^Data of 260 patients were available

^e^Data of 246 patients were available

^f^Data of 275 patients were available

^g^Data of 267 patients were available

^h^Data of 285 patients were available

^i^Data of 280 patients were available

###### 

Relationships between HBV infection and patient characteristics

  Clinicaopathological features                               HBV infection (n=35)   HBV non-infection (n=254)   *P* value
  --------------------------------------- ------------------- ---------------------- --------------------------- -----------
  Age (years)                             \<=57               20                     130                         0.508
                                          \>57                15                     124                         
  Sex                                     Male                22                     163                         0.879
                                          Female              13                     91                          
  T stage^a^                              T1-3                25                     145                         0.079
                                          T4                  7                      88                          
  N stage^b^                              N0                  15                     95                          0.577
                                          N1-2                17                     133                         
  Primary tumor location^c^               Left-sided colon    13                     99                          0.221
                                          Right-sided colon   12                     55                          
                                          Rectum              10                     99                          
  Primary tumor size (cm)^d^              \<=4                13                     113                         0.085
                                          \>4                 15                     65                          
  Histological grade^e^                   Well/Moderate       27                     185                         0.518
                                          Poor                3                      31                          
  Albumin (g/dL)                          \<=35               34                     238                         0.668
                                          \>35                1                      16                          
  Total bilirubin (mg/dL)                 \<=20.5             34                     244                         1.000
                                          \>20.5              1                      10                          
  LDH (IU/L)                              \<=245              32                     222                         0.683
                                          \>245               3                      32                          
  GGT (IU/L)^c^                           \<=50               27                     188                         0.718
                                          \>50                8                      65                          
  Liver matastases segments               Oligo               19                     117                         0.361
                                          Multiple            16                     137                         
  Liver matastases numbers                Single              24                     123                         0.025
                                          Multiple            11                     131                         
  Liver metastasis timing                 Synchronous         27                     163                         0.130
                                          Metachronous        8                      91                          
  Liver metastases largest size (cm)^f^   \<=2.5              24                     127                         0.049
                                          \>2.5               11                     123                         
  Surgical margin (cm)^g^                 \<=0.5              9                      84                          0.778
                                          \>0.5               9                      73                          
  CEA level (ng/ml)^h^                    \<=5                16                     86                          0.149
                                          \>5                 17                     156                         
  CA199 level (U/ml)^i^                   \<=35               21                     164                         0.843
                                          \>35                10                     72                          
  Neoadjuvant chemotherapy                Yes                 14                     126                         0.286
                                          No                  21                     128                         
  Adjuvant chemotherapy                   Yes                 7                      81                          0.152
                                          No                  28                     173                         

Abbreviations: HBV, hepatitis B virus; LDH, lactate dehydrogenase; GGT, gamma-glutamyl transpeptidase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

^a^Data of 265 patients were available

^b^Data of 260 patients were available

^c^Data of 288 patients were available

^d^Data of 206 patients were available

^e^Data of 246 patients were available

^f^Data of 285 patients were available

^g^Data of 175 patients were available

^h^Data of 275 patients were available

^i^Data of 267 patients were available

###### 

Postoperative recurrence in patients with colorectal liver-only metastases after radical liver resection between HBV infection and non-infection group

  Parameters                             HBV infection (n, %)   HBV non-infection (n, %)   *P* value
  -------------------------------------- ---------------------- -------------------------- -----------
  Median follow-up time (month, range)   33.0 (1.0-126.0)       35.0 (1.0-121.0)           0.344
  Postoperative recurrence (n=289)                                                         
  Yes                                    14 (40.0)              160(63.0)                  0.009
  No                                     21(60.0)               94(37.0)                   
  Recurrence period (n=173)                                                                
  Early recurrence (≤ 6 months)          3(21.4)                45(28.3)                   0.811
  Latter recurrence (\> 6 months)        11(78.6)               114(71.7)                  
  Recurrence pattern (n=142)                                                               
  Intrahepatic metastases                4(30.8)                76(58.9)                   0.051
  Extrahepatic metastases                9(69.2)                53(41.1)                   

Abbreviations: HBV, hepatitis B virus

###### 

Prognostic factors for OS and PFS in univariate and multivariate analysis

  Clinicaopathological features                                 OS univariate analysis   Multivariate analysis   PFS univariate analysis   Multivariate analysis                                                         
  ----------------------------------------- ------------------- ------------------------ ----------------------- ------------------------- ----------------------- --------------------- --------- --------------------- -------
  Age (years)                               ≤ 57                1.515(1.048-2.192)       0.027                   1.702(1.171-2.474)        0.005                   1.199 (0.891-1.615)   0.231                           
                                            \> 57                                                                                                                                                                        
  Gender                                    Male                1.305(0.882-1.932)       0.183                                                                     1.365 (0.991-1.880)   0.057                           
                                            Female                                                                                                                                                                       
  T stage                                   T1-3                1.154(0.772-1.725)       0.484                                                                     1.607 (0.773-1.472)   0.695                           
                                            T4                                                                                                                                                                           
  N stage                                   N0                  1.448(0.966-2.171)       0.073                                                                     1.8 (1.295-2.503)     \<0.001   2.023 (1.229-3.329)   0.006
                                            N1-2                                                                                                                                                                         
  Primary tumor location                    Left-sided colon    1.235(0.966-1.580)       0.092                                                                     1.164 (0.957-1.416)   0.127                           
                                            Right-sided colon                                                                                                                                                            
                                            Rectum                                                                                                                                                                       
  Primary tumor size (cm)                   \> 4                1.537(0.960-2.460)       0.074                                                                     1.534 (1.062-2.216)   0.023                           
                                            ≤ 4                                                                                                                                                                          
  Histological grade                        Well/Moderate       1.164(0.856-1.582)       0.334                                                                     1.097 (0.851-1.414)   0.477                           
                                            Poor                                                                                                                                                                         
  HBV infection                             Yes                 2.258(1.050-4.853)       0.037                   2.242(1.035-4.853)        0.041                   1.779 (1.030-3.072)   0.039                           
                                            No                                                                                                                                                                           
  Albumin (g/dL)                            ≤ 35                0.479(0.250-0.918)       0.027                                                                     0.590 (0.335-1.040)   0.068                           
                                            \> 35                                                                                                                                                                        
  Total bilirubin (mg/dL)                   ≤ 20.5              1.062(0.431-2.616)       0.897                                                                     1.179 (0.577-2.408)   0.652                           
                                            \> 20.5                                                                                                                                                                      
  LDH (IU/L)                                ≤ 245               1.772(1.092-2.876)       0.02                                                                      1.454 (0.957-2.209)   0.079                           
                                            \> 245                                                                                                                                                                       
  GGT (IU/L)                                ≤ 50                1.759(1.188-2.604)       0.005                   1.597(1.076-2.377)        0.021                   1.561 (1.128-2.162)   0.007     1.806 (1.099-2.967)   0.020
                                            \> 50                                                                                                                                                                        
  Liver matastases segments                 Oligo               1.815(1.241-2.655)       0.002                   1.538(1.034-2.286)        0.033                   1.847(1.360-2.507)    \<0.001                         
                                            Multiple                                                                                                                                                                     
  Liver matastases numbers                  Single              1.827 (1.256-2.657)      0.002                                                                     1.940 (1.432-2.628)   \<0.001   1.748( 1.043-2.929)   0.034
                                            Multiple                                                                                                                                                                     
  Liver metastasis timing                   Synchronous         0.920 (0.628-1.348)      0.668                                                                     0.964 (0.704-1.319)   0.818                           
                                            Metachronous                                                                                                                                                                 
  Liver metastases largest size (cm)        ≤ 2.5               1.329 (0.915-1.932)      0.136                                                                     1.355 (1.002-1.831)   0.048                           
                                            \> 2.5                                                                                                                                                                       
  Surgical margin of liver resection (cm)   \> 0.5              1.583 (0.985-2.543)      0.058                                                                     1.755(1.195-2.578)    0.004                           
                                            ≤ 0.5                                                                                                                                                                        
  CEA level (ng/ml)                         ≤ 5                 1.137 (0.769-1.681)      0.519                                                                     1.403(1.014-1.942)    0.041                           
                                            \> 5                                                                                                                                                                         
  CA199 level (U/ml)                        ≤ 35                1.285 (0.864-1.912)      0.216                                                                     1.125(0.809-1.566)    0.483                           
                                            \> 35                                                                                                                                                                        
  Neoadjuvant chemotherapy                  No                  1.817 (1.252-2.638)      0.002                   1.632(1.103-2.416)        0.014                   2.282(1.681-3.099)    \<0.001                         
                                            Yes                                                                                                                                                                          
  Adjuvant chemotherapy                     No                  0.964 (0.650-1.430)      0.854                                                                     0.943(0.681-1.305)    0.723                           
                                            Yes                                                                                                                                                                          

Abbreviations: OS, overall survival; PFS, progression-free survival; HBV, hepatitis B virus; LDH, lactate dehydrogenase; GGT, gamma-glutamyl transpeptidase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.
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